KIDS icon

OrthoPediatrics

27.16 USD
+0.63
2.37%
At close Jan 17, 4:00 PM EST
After hours
27.16
+0.00
0.00%
1 day
2.37%
5 days
11.72%
1 month
20.93%
3 months
1.12%
6 months
-23.26%
Year to date
18.76%
1 year
-3.24%
5 years
-43.18%
10 years
41.31%
 

About: OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.

Employees: 247

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5,350% more call options, than puts

Call options by funds: $436K | Put options by funds: $8K

33% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 9

33% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 36

2% more funds holding

Funds holding: 122 [Q2] → 124 (+2) [Q3]

2.07% less ownership

Funds ownership: 69.61% [Q2] → 67.54% (-2.07%) [Q3]

7% less capital invested

Capital invested by funds: $477M [Q2] → $443M (-$33.8M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$25
8%
downside
Avg. target
$34
23%
upside
High target
$42
55%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Needham
Mike Matson
52% 1-year accuracy
64 / 122 met price target
55%upside
$42
Buy
Reiterated
14 Jan 2025
Truist Securities
Richard Newitter
79% 1-year accuracy
33 / 42 met price target
8%downside
$25
Hold
Maintained
18 Dec 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance
Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-YearInitiates guidance for record adjusted EBITDA in 2025
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance
Neutral
GlobeNewsWire
1 week ago
OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division
WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the rapid expansion of its Specialty Bracing (OPSB) division with entrance into 3 target markets within Indiana, Colorado, and Florida.
OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division
Neutral
GlobeNewsWire
1 month ago
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Products
WARSAW, Ind., Dec. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics today announced that the OrthoPediatrics Specialty Bracing (OPSB™) division is expanding its product offering with the launch of two new products including the OPSB Sensor System and MOVE-D™.
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Products
Neutral
GlobeNewsWire
1 month ago
OrthoPediatrics Corp. to Host Educational and Networking Events at 20th Annual International Pediatric Orthopaedic Symposium (IPOS)
WARSAW, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its continued support of the event as an Emerald-Level sponsor.
OrthoPediatrics Corp. to Host Educational and Networking Events at 20th Annual International Pediatric Orthopaedic Symposium (IPOS)
Neutral
GlobeNewsWire
1 month ago
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with DF2® Brace
WARSAW, Ind., Nov. 26, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company dedicated exclusively to advancing the field of pediatric orthopedics, is excited to announce significant updates to the DF2® Brace, a cornerstone product within the OrthoPediatrics Specialty Bracing business (“OPSB”). The DF2 Brace updates include expanded indications for use, enhanced sizing options, and additional international markets.
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with DF2® Brace
Neutral
Seeking Alpha
2 months ago
OrthoPediatrics Corp. (KIDS) Q3 2024 Earnings Call Transcript
OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Matt O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Good morning and welcome to OrthoPediatrics Corporation's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
OrthoPediatrics Corp. (KIDS) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics
Negative
Zacks Investment Research
2 months ago
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago.
OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024.
OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance
Neutral
GlobeNewsWire
2 months ago
OrthoPediatrics Corp. to Report Third Quarter 2024 Financial Results on November 7, 2024
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results.
OrthoPediatrics Corp. to Report Third Quarter 2024 Financial Results on November 7, 2024
Charts implemented using Lightweight Charts™